patent.fyi
Applications  /  US 2026/0355149
United States Patent Application Publication

US 2026/0355149 A1

Published
Nov 12, 2026
Filed
Jul 17, 2026
Earliest date on the face
Dec 10, 2021
Classification
A61K 31/375
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Lower ascorbic acid concentration

What ifWhat if the injectable solution contains 10 mg/mL of ascorbic acid?
Claim language“15-50 mg/mL”

A 10 mL fill supplies 100 mg of ascorbic acid, the same amount as a 5 mL fill at 20 mg/mL. The larger fill volume preserves the amount delivered per unit.

1.2Calcium disodium edetate chelation

What ifWhat if calcium disodium edetate replaces edetate disodium as the chelating ingredient?
Claim language“comprising edetate disodium”

Calcium disodium edetate supplies edetate with calcium already bound. Trace copper ions displace the bound calcium, reducing the free copper available to catalyze ascorbate oxidation.

1.3Oxygen control through packaging

What ifWhat if nitrogen purging and a sealed glass ampoule provide oxidation control?
Claim language“antioxidant component”

Nitrogen sparging lowers dissolved oxygen before filling, and a nitrogen flush displaces air from the ampoule headspace. Flame sealing the glass neck limits oxygen entry during storage.

1.4Lower concentration acetate buffer

What ifWhat if the solution uses an acetate buffer at 0.20% w/v total acetate ingredients?
Claim language“a buffer component in a concentration of about 0.5% w/v-1.5% w/v”

Sodium acetate and acetic acid form a buffer pair that takes up added acid or base. Their ratio is set in the final solution to reach pH 5.0, and the sealed container limits carbon dioxide exchange during storage.

1.6Concentrate diluted before infusion

What ifWhat if the dose is supplied as a sterile concentrate that requires dilution before infusion?
Claim language“does not require dilution”

A measured volume of concentrate is transferred aseptically into a compatible sterile infusion fluid. Mixing distributes the ascorbic acid, and the selected final volume sets its infusion concentration.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Ascorbic acid ampoules for instrument checks

Sealed single-use ampoules contain an aqueous solution of ascorbic acid, edetate disodium, sodium metabisulfite, and an acetate buffer. A laboratory dilutes the ampoule contents into the mobile phase and analyzes the solution by liquid chromatography with ultraviolet detection. A separately prepared ascorbic acid reference establishes the expected retention time, and the ampoule solution checks retention time and detector response during routine instrument operation.

Component substitution

Citrate buffer for the injectable solution

Citric acid and sodium citrate form the buffer in an aqueous solution containing ascorbic acid, edetate disodium, and a separate sodium metabisulfite antioxidant. The ratio of the citrate species sets the solution pH, and the total citrate concentration sets the buffer capacity and contributes to osmolality. A formulation study measures pH, osmolality, and ascorbic acid assay at filling and during storage to select the buffer composition.

Parameter or scale variation

Two fill volumes at fixed concentration

A common bulk solution contains 25 mg/mL ascorbic acid, edetate disodium, a separate antioxidant, an acetate buffer, and water for injection. The filling line dispenses 2 mL or 4 mL into single-dose vials, yielding nominal vial contents of 50 mg or 100 mg of ascorbic acid, respectively. Each fill configuration undergoes testing for extractable volume and container closure integrity, and the stability study compares both configurations after three months at 20 to 25 °C.

Reduced oxygen headspace in sealed vials

Single-dose glass vials contain the buffered aqueous ascorbic acid solution with edetate disodium and a separate antioxidant. The filling line flushes the vial headspace with nitrogen immediately before stoppering and targets residual headspace oxygen of 2% by volume or less. A headspace oxygen analyzer checks sealed samples, and a three-month study at 20 to 25 °C tracks ascorbic acid content and oxidation products.

Combination with existing systems

Prefilled syringe for syringe pump delivery

The buffered aqueous ascorbic acid solution contains edetate disodium and a separate antioxidant and is supplied in a sterile, single-use prefilled syringe. The syringe barrel and plunger dimensions match a supported syringe profile in a programmable syringe pump. The pump advances the plunger at the configured volumetric rate through a compatible administration line. Compatibility testing measures delivered volume and ascorbic acid recovery after contact with the syringe and line.

Automated or data-driven variant

Automated checks during solution filling

A dissolved-oxygen probe and a pH probe monitor a recirculation loop on the holding vessel for the buffered ascorbic acid solution. The controller logs both measurements by batch and pauses filling when either reading moves outside its configured range. An inline checkweigher compares filled vial masses with limits derived from the target fill volume, measured solution density, and vial tare. The batch record links sensor readings, fill checks, and rejected units to the filling run.

Specific version of a part

Ascorbic acid at 25 mg/ml

Ascorbic acid is dissolved in an aqueous carrier at a final concentration of 25 mg/mL. A 4 mL fill contains 100 mg of ascorbic acid.

Edetate disodium trace metal control

Edetate disodium is dissolved at 0.01% w/v, or 0.1 mg/mL. The chelator binds trace metal ions such as copper and reduces the free metal available to catalyze oxidation.

Sodium metabisulfite antioxidant

Sodium metabisulfite is added at 0.10% w/v as a separate dissolved ingredient. It forms bisulfite in water, and the resulting sulfite species react with dissolved oxygen.

Water for injection carrier

Water for injection dissolves the ascorbic acid and the water-soluble excipients. Additional water for injection brings the mixed batch to its specified final volume before sterile filtration and aseptic filling.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 8,647,572 B1
Published
Feb 11, 2014
Filed
Aug 21, 2012
Class
G01N 21/00
Document BUS 2020/0188478 A1
Published
Jun 18, 2020
Filed
Dec 12, 2019
Class
A61K 38/14
Claim 1
Document A
Document B
1.1(a) an ascorbic acid compound component comprising ascorbic acid in a concentration of about 15-50 mg/mL;
(1) providing a fresh produce treatment comprised of water and ascorbic acid;
A · US 8,647,572 B1 · ¶ 16
1.2(b) a chelation component comprising edetate disodium in a concentration of about 0.001% w/v to about 0.1% w/v;
(ii) a chelating agent selected from edetate disodium (disodium EDTA), edetate disodium (disodium EDTA) anhydrous, edetate sodium, edetate calcium disodium, edetate calcium di sodium anhydrous, edetic acid and a mixture thereof;
B · US 2020/0188478 A1 · ¶ 69
1.3(c) antioxidant component, not comprising any ingredient of the chelation component, which is present in a concentration of about 0.05% w/v~0.2% w/v;
Name of Ingredient (Role of ingredient) Example-1 Example-2 Example-3 Example-4 Example-5 Example-6 Vancomycin# 5 mg/mL 5 mg/mL 5 mg/mL 5 mg/mL 5 mg/mL 5 mg/mL (Active) Sodium chloride 8 mg/mL 8 mg/mL 1 mg/mL 1 mg/mL 1 mg/mL 8 mg/mL (Tonicity modifying agent) Dextrose — — — — — — (Tonicity modifying agent) L-methioninc 20 mg/mL 40 mg/mL 40 mg/mL 40 mg/mL — 20 mg/mL (Anti-oxidant/stabilizer) Sodium hydroxide Q.S.* Q.S.* Q.S.* Q.S.* Q.S.* — (pH adjusting agent) Triethanolamine
B · US 2020/0188478 A1 · ¶
1.4(d) a buffer component in a concentration of about 0.5% w/v-1.5% w/v; and
Name of Ingredient (Role of ingredient) Example-7 Example-8 Example-9 Example-10 Example-11 Example-12 Vancomycin# (Active) 5 mg/mL 5 mg/mL 5 mg/mL 5 mg/mL 5 mg/mL 5 mg/mL Mannitol — — 20 mg/mL — 20 mg/mL — (Tonicity modifying agent) L-methionine 20 mg/mL — 20 mg/mL — — — (Stabilizer) Polyvinyl pyrrolidone — — — 20 mg/mL 20 mg/mL — (Stabilizer) Polyethylene glycol-400 — 20 mg/mL 20 mg/mL — 20 mg/mL — (co-solvent/solubilizer) Poloxamer — — — — — 6 mg/mL (co-solvent/solubilizer
B · US 2020/0188478 A1 · ¶
1.5(e) a pharmaceutically acceptable carrier,
(iii) a vehicle selected from water such as water for injection; and (iv) optionally a pharmaceutically acceptable excipient.
B · US 2020/0188478 A1 · ¶ 69
1.6wherein the composition does not comprise a tonicity agent, does not require dilution, reconstitution, or further manipulation prior to administration to a patient, and is stable when stored at 20 °C to 25 °C±2 °C for at least 3 months.
(d) The Vancomycin formulation of the present invention is stable for prolonged time, say for example at least for three months or more. Further, no special storage conditions (such as storing at −20° C.) are required to achieve the prolonged stability.
B · US 2020/0188478 A1 · ¶ 21

An empty cell means only that no passage was reproduced there.

Statements in these documents
Ascorbate compound solution is used as an anti-oxidant dip for the prevention of the browning of fruit and vegetable surfaces, and preserving the appearance, texture, crispness and color of fresh cut or minimally processed fruits and vegetables, such as apples.
A · US 8,647,572 B1 · ¶ 5
Proper management via continuous or continual monitoring and control of ascorbate concentration levels in the dip tank during processing enhances the effectiveness of the ascorbate as a preservative for fresh fruit and vegetables.
A · US 8,647,572 B1 · ¶ 5
Both processes may involve (i) stability concerns of the diluted solutions and (ii) dosing errors & cross contamination while diluting with diluent before administration to patient.
B · US 2020/0188478 A1 · ¶ 1
It is therefore advantageous to have pre-mixed, ready-to-use injectable solution which does not require reconstitution or dilution before administration.
B · US 2020/0188478 A1 · ¶ 1
Cite aspatent.fyi, US 2026/0355149 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355149/, SHA-256 2eb164297e1e314502320393aad6205fb8cef54b95fcde4630f2cab30c513730
First published
Permanent addresshttps://patent.fyi/US20260355149/
Content fingerprint (SHA-256)2eb164297e1e314502320393aad6205fb8cef54b95fcde4630f2cab30c513730
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi